AEGiS-WSJ: Technology Brief -- NEXSTAR PHARMACEUTICALS INC.: Approval of DaunoXome Set by European Countries Wall Street JournalImportant note: Information in this article was accurate in 1996. The state of the art may have changed since the publication date.
Click here to return to Wall Street Journal main menu




DonateNow



Technology Brief -- NEXSTAR PHARMACEUTICALS INC.: Approval of DaunoXome Set by European Countries

The Wall Street Journal - 22 Feb 1996

NeXstar Pharmaceuticals Inc., Boulder, Colo., said 10 European Community countries notified it that they will approve, within the next few weeks, the marketing of a new NeXstar drug for use in treating AIDS-related Kaposi's sarcoma. Austria, Belgium, Denmark, Germany, Greece, Ireland, Italy, Luxembourg, the Netherlands and Portugal agreed to approve the drug, DaunoXome, at a recent meeting in London, after reviewing data from clinical trials, the company said. The drug gained earlier approval for use in Sweden and the United Kingdom. DaunoXome is awaiting approval from the U.S. Food and Drug Administration, as well as from separate applications pending in France, Switzerland, Norway, Finland and Canada.


960222
WJ960209

Copyright © 1996 - The Wall Street Journal. Reproduction of this article (other than one copy for personal reference) must be cleared through the WSJ Permissions Desk.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Elton John AIDS Foundation UK, the National Library of Medicine, AIDS Walk of Orange County, and donations from users like you.

Always watch for outdated information. This article first appeared in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1996. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .